tickdelta
tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

DHRDanaher Corporation

Health care · Industrial Instruments · NYSE

Danaher is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. 10-K, Item 1

DHR quote by TradingView
Employees
60,000
Headquarters
Washington, DC
CEO
Rainer Blair
Next results
around Jan 11, 2027
Compare with peers → Embed
All key numbers (41, from the latest 10-K and 10-Q) From EDGAR
EPS (ttm)6.10Sales (ttm)25.6BNet income (ttm)4.3BSales growth+2.9%EPS growth-4.5%Sales Q/Q+8.3%
Free cash flow5.7BGross margin58.6%Oper. margin20.4%Net margin16.9%FCF margin22.4%ROE8.1%
ROA4.6%R&D / sales6.5%Dividend-Debt/Eq0.53Curr. ratio1.63Cash5.7B
Op. cash flow (ttm)6.9BEBITDA5.4BEBITDA margin22.1%Net debt22.9BQuick ratio1.36Interest cover17.70
ROIC4.9%Tax rate15.0%Stock pay / sales1.2%Shares out.703.5MShares Y/Y-2.9%Book / share76.22
Cash / share8.08Sales / share36.40Asset turnover0.27Inventory turns4.04Days sales out.58Sales 3Y CAGR-2.7%
Sales 5Y CAGR+2.0%EPS 3Y CAGR-19.4%EPS 5Y CAGR+0.6%Employees60,000Sales / employee427K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

DHR against Health care peers

Ten years, side by side → · All 60 →
GrowthProfitBalanceCleanInsiders
DHRPeer median

Each side 0 to 100, ranked against every company we cover: relative position on reported figures, not a buy score. How

Every dot is one of the 60 companies, the better end on the right. Hover a dot for the company.

Sales growth
+2.9%46th of 60 · median +7.1%
Net margin
16.9%16th of 60 · median 9.6%
Return on equity
8.1%36th of 54 · median 13.1%
Free cash flow margin
22.4%12th of 56 · median 15.5%
Debt / equity (less is better)
0.5315th of 49 · median 0.66
DHR and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthGross marginNet marginROEFCF marginDebt / equity
DHR Danaher Corporation$25.6B +2.9%58.6%16.9%8.1%22.4%0.53
GILD Gilead Sciences$31.0B +2.4%79.9%-12.5%-29.6%44.5%2.01
SYK Stryker Corporation$26.3B +11.2%65.3%13.8%15.4%17.4%0.61
BDX Becton Dickinson$22.5B +8.2%46.9%4.2%3.9%14.2%0.69
GEHC GE HealthCare$21.6B +4.8%39.9%10.0%18.5%8.7%0.86
BSX Boston Scientific$21.1B +19.9%69.1%16.6%13.7%15.8%0.47

From $24.8B of sales to $6.4B of profit

FY2021, from the 10-K income statement
Revenue to Gross profit: $15.2BRevenue to Cost of revenue: $9.6BGross profit to Operating profit: $6.4BGross profit to Operating expenses: $8.9BOperating profit to Net profit: $5.3BOperating profit to Tax: $1.1BOther income to Net profit: $1.1BOperating expenses to R&D: $1.5BOperating expenses to Sales, admin & other: $7.4B Revenue: $24.8B Revenue$24.8B +11% Y/Y Gross profit: $15.2B · 61% margin Gross profit$15.2B61% margin +22% Y/Y Cost of revenue: $9.6B · 39% of revenue Cost of revenue$9.6B39% of revenue Operating profit: $6.4B · 26% margin Operating profit$6.4B26% margin +51% Y/Y Other income: $1.1B · 5% of revenue Other income$1.1B5% of revenue Operating expenses: $8.9B · 36% of revenue Operating expenses$8.9B36% of revenue Net profit: $6.4B · 26% margin Net profit$6.4B26% margin +76% Y/Y Tax: $1.1B · 4% of revenue Tax$1.1B4% of revenue R&D: $1.5B · 6% of revenue R&D$1.5B6% of revenue Sales, admin & other: $7.4B · 30% of revenue Sales, admin & other$7.4B30% of revenue

Swipe sideways for the whole flow →

From $26.6B of sales to $7.2B of profit

FY2022, from the 10-K income statement and revenue by product
Recurring to Revenue: $20.9BNonrecurring to Revenue: $5.8BRevenue to Gross profit: $16.2BRevenue to Cost of revenue: $10.5BGross profit to Operating profit: $7.5BGross profit to Operating expenses: $8.7BOperating profit to Net profit: $6.7BOperating profit to Tax: $818.0MOther income to Net profit: $491.0MOperating expenses to R&D: $1.5BOperating expenses to SG&A: $7.1B Recurring: $20.9B · 78% Recurring$20.9B78% Nonrecurring: $5.8B · 22% Nonrecurring$5.8B22% Revenue: $26.6B Revenue$26.6B +7% Y/Y Gross profit: $16.2B · 61% margin Gross profit$16.2B61% margin +6% Y/Y Cost of revenue: $10.5B · 39% of revenue Cost of revenue$10.5B39% of revenue Operating profit: $7.5B · 28% margin Operating profit$7.5B28% margin +18% Y/Y Other income: $491.0M · 2% of revenue Other income$491.0M2% of revenue Operating expenses: $8.7B · 32% of revenue Operating expenses$8.7B32% of revenue Net profit: $7.2B · 27% margin Net profit$7.2B27% margin +12% Y/Y Tax: $818.0M · 3% of revenue Tax$818.0M3% of revenue R&D: $1.5B · 6% of revenue R&D$1.5B6% of revenue SG&A: $7.1B · 27% of revenue SG&A$7.1B27% of revenue

Swipe sideways for the whole flow →

From $23.9B of sales to $4.8B of profit

FY2023, from the 10-K income statement and revenue by product
Recurring to Revenue: $18.7BNonrecurring to Revenue: $5.2BRevenue to Gross profit: $14.0BRevenue to Cost of revenue: $9.9BGross profit to Operating profit: $5.2BGross profit to Operating expenses: $8.8BOperating profit to Net profit: $4.4BOperating profit to Tax: $823.0MOther income to Net profit: $385.0MOperating expenses to R&D: $1.5BOperating expenses to SG&A: $7.3B Recurring: $18.7B · 78% Recurring$18.7B78% Nonrecurring: $5.2B · 22% Nonrecurring$5.2B22% Revenue: $23.9B Revenue$23.9B −10% Y/Y Gross profit: $14.0B · 59% margin Gross profit$14.0B59% margin −13% Y/Y Cost of revenue: $9.9B · 41% of revenue Cost of revenue$9.9B41% of revenue Operating profit: $5.2B · 22% margin Operating profit$5.2B22% margin −31% Y/Y Other income: $385.0M · 2% of revenue Other income$385.0M2% of revenue Operating expenses: $8.8B · 37% of revenue Operating expenses$8.8B37% of revenue Net profit: $4.8B · 20% margin Net profit$4.8B20% margin −34% Y/Y Tax: $823.0M · 3% of revenue Tax$823.0M3% of revenue R&D: $1.5B · 6% of revenue R&D$1.5B6% of revenue SG&A: $7.3B · 31% of revenue SG&A$7.3B31% of revenue

Swipe sideways for the whole flow →

From $23.9B of sales to $3.9B of profit

FY2024, from the 10-K income statement and revenue by product
Recurring to Revenue: $19.4BNonrecurring to Revenue: $4.5BRevenue to Gross profit: $14.2BRevenue to Cost of revenue: $9.7BGross profit to Operating profit: $4.9BGross profit to Operating expenses: $9.3BOperating profit to Net profit: $3.9BOperating profit to Tax & other: $964.0MOperating expenses to R&D: $1.6BOperating expenses to SG&A: $7.8B Recurring: $19.4B · 81% Recurring$19.4B81% Nonrecurring: $4.5B · 19% Nonrecurring$4.5B19% Revenue: $23.9B Revenue$23.9B +0% Y/Y Gross profit: $14.2B · 60% margin Gross profit$14.2B60% margin +1% Y/Y Cost of revenue: $9.7B · 40% of revenue Cost of revenue$9.7B40% of revenue Operating profit: $4.9B · 20% margin Operating profit$4.9B20% margin −7% Y/Y Operating expenses: $9.3B · 39% of revenue Operating expenses$9.3B39% of revenue Net profit: $3.9B · 16% margin Net profit$3.9B16% margin −18% Y/Y Tax & other: $964.0M · 4% of revenue Tax & other$964.0M4% of revenue R&D: $1.6B · 7% of revenue R&D$1.6B7% of revenue SG&A: $7.8B · 32% of revenue SG&A$7.8B32% of revenue

Swipe sideways for the whole flow →

From $24.6B of sales to $3.6B of profit

FY2025, from the 10-K income statement and revenue by product
Recurring to Revenue: $20.1BNonrecurring to Revenue: $4.4BRevenue to Gross profit: $14.5BRevenue to Cost of revenue: $10.0BGross profit to Operating profit: $4.7BGross profit to Operating expenses: $9.8BOperating profit to Net profit: $3.6BOperating profit to Tax & other: $1.1BOperating expenses to R&D: $1.6BOperating expenses to SG&A: $8.2B Recurring: $20.1B · 82% Recurring$20.1B82% Nonrecurring: $4.4B · 18% Nonrecurring$4.4B18% Revenue: $24.6B Revenue$24.6B +3% Y/Y Gross profit: $14.5B · 59% margin Gross profit$14.5B59% margin +2% Y/Y Cost of revenue: $10.0B · 41% of revenue Cost of revenue$10.0B41% of revenue Operating profit: $4.7B · 19% margin Operating profit$4.7B19% margin −4% Y/Y Operating expenses: $9.8B · 40% of revenue Operating expenses$9.8B40% of revenue Net profit: $3.6B · 15% margin Net profit$3.6B15% margin −7% Y/Y Tax & other: $1.1B · 4% of revenue Tax & other$1.1B4% of revenue R&D: $1.6B · 7% of revenue R&D$1.6B7% of revenue SG&A: $8.2B · 34% of revenue SG&A$8.2B34% of revenue

Swipe sideways for the whole flow →

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • Sales, admin & other
  • Net profit
  • R&D
  • Tax & other

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement →

Profitability

3 of 4
  • ✓
    Net margin above the peer median16.9% vs 9.6%
  • ✓
    Gross margin up over 5 years56.0% → 59.1%
  • !
    Return on equity below 15%8.1%
  • ✓
    A profit in every one of 10 years
Net margin, FY2016 to FY2025: 15.1% → 14.7%

Balance sheet

3 of 4
  • ✓
    Interest covered more than 5 timesOperating income is 17.7× interest expense
  • ✓
    Debt smaller than equityDebt / equity 0.53 on the latest balance sheet (peer median 0.66)
  • ✓
    Current assets cover current liabilitiesCurrent ratio 1.63
  • !
    Net debt over 3 years of free cash flow$22.9B net debt, 4.0 years
Debt / equity at each year end, FY2016 to FY2025: 0.65 → 0.35
What the debt is made of ↓

Cash and shareholders

3 of 3
  • ✓
    Free cash flow positive in every one of 10 years$5.3B last year
  • ✓
    Share count down over 5 years−0.4%
  • ✓
    Cash from operations above net income$6.4B vs $3.6B
Free cash flow, FY2016 to FY2025: 2.9B → 5.3B

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

What the debt is made of, and when it is due

balance sheet of Sep 25, 2026 · schedule of Dec 31, 2025
Debt: $28.6B Debt$28.6B Long-term debt: $26.5B · 93% Long-term debt$26.5B · 93% Short-term debt: $2.1B · 7% Short-term debt$2.1B · 7% Next 12 months: $2.4B · 8% Next 12 months$2.4B · 8% Year 2: $2.3B · 8% Year 2$2.3B · 8% Year 3: $1.7B · 6% Year 3$1.7B · 6% Year 4: $1.2B · 4% Year 4$1.2B · 4% Year 5: $935.0M · 3% Year 5$935.0M · 3% After year 5: $9.8B · 34% After year 5$9.8B · 34%

The debt note's own lines, 2025-12-31

Fixed rate $0Floating $4.4B Not stated $17.8B

Line, as the company names itKindRateFixed or floatingAmount
Euro-Denominated Commercial Paper, 2026 Biopharma Euro Notes and 2026 Euro NotesCommercial paper–floating$3.5B
0.75% senior unsecured notes due 2031 (Senior Notes)Secured0.75%not stated$2.0B
0.2% senior unsecured notes due 2026 (Senior Notes)Secured0.20%not stated$1.5B
0.45% senior unsecured notes due 2028 (Senior Notes)Secured0.45%not stated$1.5B
1.35% senior unsecured notes due 2039 (Senior Notes)Secured1.35%not stated$1.5B
2.8% senior unsecured notes due 2051 (Senior Notes)Secured2.80%not stated$985.0M
2.6% senior unsecured notes due 2050 (Senior Notes)Secured2.60%not stated$983.0M
2.1% senior notes due 2026 (Senior Notes)Notes and bonds2.10%not stated$940.0M
2.5% senior notes due 2030 (Senior Notes)Notes and bonds2.50%not stated$940.0M
Euro-denominated commercial paper (Commercial Paper)Commercial paper2.20%floating$933.0M
3.25% senior unsecured notes due 2039 (Senior Notes)Secured3.25%not stated$892.0M
3.4% senior unsecured notes due 2049 (Senior Notes)Secured3.40%not stated$891.0M
1.8% senior unsecured notes due 2049 (Senior Notes)Secured1.80%not stated$873.0M
2.6% senior unsecured notes due 2029 (Senior Notes)Secured2.60%not stated$798.0M
1.2% senior unsecured notes due 2027 (Senior Notes)Secured1.20%not stated$704.0M
3.35% senior unsecured notes due 2025 (Senior Notes)Secured3.35%not stated$500.0M
4.375% senior unsecured notes due 2045 (Senior Notes)Secured4.38%not stated$500.0M
2029 CHF Bonds (Bonds)Notes and bonds0.89%not stated$409.0M
2033 CHF Bonds (Bonds)Notes and bonds1.26%not stated$408.0M
0.65% senior unsecured notes due 2032 (Senior Notes)Secured0.65%not stated$339.0M
2027 CHF Bonds (Bonds)Notes and bonds0.48%not stated$315.0M
2037 CHF Bonds (Bonds)Notes and bonds1.62%not stated$282.0M
1.125% senior unsecured bonds due 2028 (Bonds)Secured1.12%not stated$267.0M
0.3% senior unsecured notes due 2027 (Senior Notes)Secured0.30%not stated$196.0M
2045 CHF Bonds (Bonds)Notes and bonds1.94%not stated$157.0M
Other––not stated$1.0M
All 26 lines

From the debt note in the 10-K's XBRL (0000313616-26-000062), as the company tags it: by issue, by year, by currency or by kind. Lines from two ways of cutting the same debt can overlap, so they are not added up. Fixed or floating is read from the line's own name only; "not stated" when it says neither.

Left: the debt lines on the balance sheet (XBRL). Right: the principal due each year, from the debt note's maturity schedule; it can differ a little from the balance sheet, which shows the debt net of discounts and fees. Leases are not counted. The full schedule →

Revenue and net income, FY2016 to FY2025

Revenue 24.6B Net income 3.6B
FY2016 revenue 16.9B · Revenues, 0000313616-19-000035 FY2016 net income 2.6B · NetIncomeLoss, 0000313616-19-000035 16.9B FY2016 FY2017 revenue 18.3B · Revenues, 0000313616-19-000035 FY2017 net income 2.5B · NetIncomeLoss, 0000313616-20-000041 18.3B FY2017 FY2018 revenue 19.9B · Revenues, 0000313616-19-000035 FY2018 net income 2.7B · NetIncomeLoss, 0000313616-21-000045 19.9B FY2018 FY2019 revenue 17.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-22-000061 FY2019 net income 3.0B · NetIncomeLoss, 0000313616-22-000061 17.9B FY2019 FY2020 revenue 22.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-23-000087 FY2020 net income 3.6B · NetIncomeLoss, 0000313616-23-000087 22.3B FY2020 FY2021 revenue 24.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-24-000052 FY2021 net income 6.4B · NetIncomeLoss, 0000313616-24-000052 24.8B FY2021 FY2022 revenue 26.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-25-000043 FY2022 net income 7.2B · NetIncomeLoss, 0000313616-25-000043 26.6B FY2022 FY2023 revenue 23.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-26-000062 FY2023 net income 4.8B · NetIncomeLoss, 0000313616-26-000062 23.9B FY2023 FY2024 revenue 23.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-26-000062 FY2024 net income 3.9B · NetIncomeLoss, 0000313616-26-000062 23.9B FY2024 FY2025 revenue 24.6B · RevenueFromContractWithCustomerExcludingAssessedTax, 0000313616-26-000062 FY2025 net income 3.6B · NetIncomeLoss, 0000313616-26-000062 24.6B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. Full financials →

DHR's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Annual Quarterly
Revenue24.6B
FY2016: 16.9BFY2017: 18.3BFY2018: 19.9BFY2019: 17.9BFY2020: 22.3BFY2021: 24.8BFY2022: 26.6BFY2023: 23.9BFY2024: 23.9BFY2025: 24.6B FY2017FY2019FY2021FY2023FY2025
Net income3.6B
FY2016: 2.6BFY2017: 2.5BFY2018: 2.7BFY2019: 3.0BFY2020: 3.6BFY2021: 6.4BFY2022: 7.2BFY2023: 4.8BFY2024: 3.9BFY2025: 3.6B FY2017FY2019FY2021FY2023FY2025
Free cash flow5.3B
FY2016: 2.9BFY2017: 2.9BFY2018: 3.4BFY2019: 3.3BFY2020: 5.4BFY2021: 7.1BFY2022: 7.4BFY2023: 5.8BFY2024: 5.3BFY2025: 5.3B FY2017FY2019FY2021FY2023FY2025
EPS (diluted)5.05
FY2016: 3.65FY2017: 3.53FY2018: 3.74FY2019: 4.05FY2020: 4.89FY2021: 8.61FY2022: 9.66FY2023: 6.38FY2024: 5.29FY2025: 5.05 FY2017FY2019FY2021FY2023FY2025
Diluted shares716.1M
FY2016: 699.8MFY2017: 706.1MFY2018: 710.2MFY2019: 725.5MFY2020: 718.7MFY2021: 736.8MFY2022: 737.1MFY2023: 743.1MFY2024: 737.2MFY2025: 716.1M FY2017FY2019FY2021FY2023FY2025

Revenue by business segment

year to Dec 31, 2025
RevenueSharevs year before
Diagnostics 9.9B40.5% +1.6%
Life Sciences 7.3B29.9% +0.1%
Biotechnology 7.3B29.7% +7.9%

10-K 0000313616-26-000062, segment and revenue notes (XBRL).

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Recurring 20.1B81.9% +3.9%
Nonrecurring 4.4B18.1% -1.5%

10-K 0000313616-26-000062, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
North America 10.4B42.2% +0.6%
High-growth markets 7.0B28.6% +2.2%
Western Europe 5.9B24.2% +8.8%
Other developed markets 1.3B5.1% -0.1%

10-K 0000313616-26-000062, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue16.9B18.3B19.9B17.9B22.3B24.8B26.6B23.9B23.9B24.6B
Cost of revenue7.5B6.9B7.5B7.9B9.8B9.6B10.5B9.9B9.7B10.0B
Gross profit9.3B8.6B9.5B10.0B12.5B15.2B16.2B14.0B14.2B14.5B
R&D975.1M956.4M1.1B1.1B1.3B1.5B1.5B1.5B1.6B1.6B
SG&A5.6B5.0B5.4B5.6B6.9B6.8B7.1B7.3B7.8B8.2B
Operating income2.7B2.6B3.1B3.3B4.2B6.4B7.5B5.2B4.9B4.7B
Interest expense184.4M140.1M137.0M108.0M275.0M231.0M204.0M286.0M278.0M265.0M
Pretax income2.6B2.5B3.0B3.3B4.5B6.5B7.1B5.0B4.6B4.2B
Income tax457.9M371.0M556.0M873.0M849.0M1.1B818.0M823.0M747.0M633.0M
Net income2.6B2.5B2.7B3.0B3.6B6.4B7.2B4.8B3.9B3.6B
EPS (diluted)3.653.533.744.054.898.619.666.385.295.05
Diluted shares699.8M706.1M710.2M725.5M718.7M736.8M737.1M743.1M737.2M716.1M
Depreciation & amortization1.1B1.1B1.2B1.2B1.8B2.1B2.1B2.2B721.0M750.0M
EBITDA3.9B3.7B4.2B4.5B6.0B8.4B9.7B7.4B5.6B5.4B
Gross margin55.3%46.8%47.8%55.7%56.0%61.4%60.8%58.7%59.5%59.1%
Operating margin16.2%14.0%15.4%18.3%19.0%25.7%28.3%21.8%20.4%19.1%
Net margin15.1%13.6%13.3%16.8%16.4%25.9%27.1%19.9%16.3%14.7%
Revenue growth-+8.6%+8.5%-10.0%+24.4%+11.3%+7.4%-10.3%-0.1%+2.9%
EPS growth--3.3%+5.9%+8.3%+20.7%+76.1%+12.2%-34.0%-17.1%-4.5%

Balance sheet

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash963.7M630.3M787.8M19.9B6.0B2.6B6.0B5.9B2.1B4.6B
Receivables3.2B3.5B3.0B3.2B4.0B4.6B4.1B3.9B3.5B3.9B
Inventory1.7B1.8B1.6B1.6B2.3B2.8B2.8B2.6B2.3B2.5B
Current assets6.7B6.8B7.1B25.6B13.8B11.6B15.9B13.9B9.5B12.8B
Property & equipment2.4B2.2B2.2B2.3B3.3B3.5B3.7B4.6B5.0B5.5B
Goodwill23.8B21.8B22.6B22.7B35.4B38.7B37.3B41.6B40.5B43.2B
Total assets45.3B46.6B47.8B62.1B76.2B83.2B84.3B84.5B77.5B83.5B
Current liabilities6.9B4.8B4.8B4.9B7.4B8.1B8.4B8.3B6.8B6.8B
Total debt14.9B10.7B9.8B21.9B21.2B22.2B20.3B20.1B16.5B18.4B
Shareholders' equity23.0B26.4B28.2B30.3B39.8B45.2B50.1B53.5B49.5B52.5B
Retained earnings20.7B22.8B25.2B24.2B27.2B32.8B39.2B41.1B44.2B46.9B

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow3.5B3.5B4.0B4.0B6.2B8.4B8.5B7.2B6.7B6.4B
Capital spending589.6M570.7M584.0M636.0M791.0M1.2B1.1B1.4B1.4B1.2B
Free cash flow2.9B2.9B3.4B3.3B5.4B7.1B7.4B5.8B5.3B5.3B
Stock-based pay (added back)129.8M127.1M138.0M159.0M187.0M184.0M295.0M306.0M288.0M298.0M
Dividends paid399.8M378.3M433.0M527.0M615.0M742.0M818.0M821.0M768.0M878.0M
Buybacks------006.0B3.1B
Acquisitions4.9B385.8M2.2B331.0M21.0B10.9B582.0M5.6B558.0M0
Debt raised3.2B1.8B012.1B------
Debt repaid2.5B668.4M507.8M1.6B------
Investing cash flow-5.2B-843.4M-2.9B-1.2B-21.2B-13.0B-2.2B-7.1B-2.0B-1.2B
Financing cash flow2.0B-3.1B-797.0M16.4B1.0B1.3B-2.6B-273.0M-8.4B-3.0B

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)129.8M127.1M138.0M159.0M187.0M184.0M295.0M306.0M288.0M298.0M
Stock-based pay / revenue0.8%0.7%0.7%0.9%0.8%0.7%1.1%1.3%1.2%1.2%
Operating lease cost---196.0M216.0M201.0M199.0M207.0M239.0M250.0M
Operating lease cash paid---202.0M221.0M197.0M219.0M214.0M245.0M250.0M
Right-of-use assets--971.0M764.0M942.0M1.0B884.0M1.1B1.1B1.2B
Operating lease liabilities--1.0B797.0M974.0M1.1B939.0M1.1B1.1B1.3B

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Work on DHR in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DHR/export.csv") into a cell.